Back to Search

LAWRENCE FLAHERTY, MD

MD

Hematology & Oncology Physician

NPI: 1124065610IndividualAccepts Medicare

Specialties, Licenses & Credentials

Internal Medicine Physician

Internal Medicine

Code: 207R00000X

4301050152(MI)
Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

4301050152(MI)

CMS Specialties

PrimaryMEDICAL ONCOLOGY

Education

SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE

Class of 1978

Research & Publications (20)

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
PMID 18620932·Lancet·2008
8-other
Biochemotherapy of melanoma.
PMID 12407509·Semin Oncol·2002
6-review
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
PMID 11432886·J Clin Oncol·2001
3-trial
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
PMID 10685653·Cancer J Sci Am·2000
3-trial
Genomics of the future: identification of quantitative trait loci in the mouse.
PMID 16339372·Genome Res·2005
6-review
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.
PMID 19540051·Int J Radiat Oncol Biol Phys·2010
8-other
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
PMID 19001327·J Clin Oncol·2008
3-trial
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
PMID 18467720·J Clin Oncol·2008
3-trial
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
PMID 17932881·Cancer·2007
3-trial
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
PMID 16937078·Invest New Drugs·2007
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
KARMANOS CANCER CENTER, 4100 JOHN R HWCRC 4TH FL
DETROIT, MI 48201

Quick Facts

NPI
1124065610
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
2
Locations
1
Years in Practice
48
Publications
20

Are you this provider?

Claim Your Profile